Brokerages expect Humana Inc (NYSE:HUM) to report $15.89 billion in sales for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Humana’s earnings, with estimates ranging from $15.87 billion to $15.91 billion. Humana posted sales of $14.26 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 11.4%. The business is expected to announce its next earnings results before the market opens on Wednesday, July 31st.
According to Zacks, analysts expect that Humana will report full year sales of $63.74 billion for the current fiscal year, with estimates ranging from $63.66 billion to $63.85 billion. For the next year, analysts forecast that the firm will report sales of $69.41 billion, with estimates ranging from $68.40 billion to $70.57 billion. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Humana.
Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, May 1st. The insurance provider reported $4.48 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.30 by $0.18. The firm had revenue of $16.11 billion during the quarter, compared to analyst estimates of $15.67 billion. Humana had a return on equity of 20.77% and a net margin of 2.99%. The business’s revenue for the quarter was up 12.8% compared to the same quarter last year. During the same period in the previous year, the company posted $3.36 EPS.
A number of brokerages have recently weighed in on HUM. Oppenheimer cut their price objective on Littelfuse from $215.00 to $210.00 and set an “outperform” rating on the stock in a report on Thursday, May 2nd. SunTrust Banks increased their price objective on Markel to $1,100.00 and gave the company a “hold” rating in a report on Thursday, May 2nd. UBS Group set a $36.00 price objective on Halliburton and gave the company a “buy” rating in a report on Tuesday, April 23rd. Zacks Investment Research lowered Hollysys Automation Technologies from a “hold” rating to a “sell” rating in a report on Thursday, April 11th. Finally, Citigroup lowered BCE from a “buy” rating to a “neutral” rating in a report on Thursday, May 2nd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the company. Humana has an average rating of “Buy” and an average price target of $336.42.
Shares of HUM traded up $2.43 during trading hours on Friday, hitting $276.87. The company had a trading volume of 868,676 shares, compared to its average volume of 1,317,996. The business’s fifty day moving average price is $266.83. Humana has a one year low of $225.65 and a one year high of $355.88. The company has a market cap of $37.28 billion, a P/E ratio of 19.03, a PEG ratio of 1.21 and a beta of 0.87. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.65 and a quick ratio of 1.65.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in HUM. Pacer Advisors Inc. increased its stake in Humana by 6,493.6% during the first quarter. Pacer Advisors Inc. now owns 12,396 shares of the insurance provider’s stock worth $3,298,000 after acquiring an additional 12,208 shares during the last quarter. Machina Capital S.A.S. acquired a new stake in Humana during the fourth quarter worth $809,000. World Asset Management Inc increased its stake in Humana by 10.9% during the first quarter. World Asset Management Inc now owns 10,840 shares of the insurance provider’s stock worth $2,883,000 after acquiring an additional 1,067 shares during the last quarter. Cribstone Capital Management LLC acquired a new stake in Humana during the first quarter worth $230,000. Finally, Deutsche Bank AG increased its stake in Humana by 13.8% during the fourth quarter. Deutsche Bank AG now owns 470,987 shares of the insurance provider’s stock worth $134,923,000 after acquiring an additional 57,106 shares during the last quarter. Institutional investors and hedge funds own 92.62% of the company’s stock.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Read More: S&P 500 Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.